Trial Profile
Relative Oral Bioavailability of a Fixed Dose Combination Tablet of BI 1356 2.5 mg / Metformin 1000 mg, Compared With Single BI 1356 2.5 mg and Metformin 1000 mg Tablets Administered Together to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2014
Price :
$35
*
At a glance
- Drugs Linagliptin/metformin (Primary) ; Linagliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 27 Jun 2014 New trial record